What this history asks
Early saline breast implant history begins with a design question rather than a marketing slogan: could a surgeon insert an empty, flexible shell through a smaller opening and fill it only after it had been positioned? In the mid-1960s, the answer led to the first clinically used inflatable saline devices. This approach did not replace the newly introduced silicone gel implant because it was automatically safer or more natural. It appeared because its construction solved a specific access and sizing problem.
To understand the early saline breast implant history, it helps to separate three things that are often blended together: the shell, the filler and the surgical method. Early saline devices still used a silicone elastomer shell. Their distinctive feature was the liquid filler and the ability to insert the device before filling it. Compared with the early silicone gel devices of the same era, that design could make the incision smaller and allow volume to be adjusted in the pocket. It also created new weak points around the valve, filling tube, folds and seams.
This article concerns the development of inflatable devices and their trade-offs, with emphasis on cosmetic augmentation. Historical reports often combine cosmetic and reconstructive cases, and the performance of a particular early model should not be treated as a prediction for a modern implant or for an individual patient. For a broader account of breast augmentation before a contained implant existed, see the planned research article on breast augmentation before silicone implants. The next historical step is covered in the 1962 first silicone breast implant.
What problem did an inflatable implant try to solve?
The first modern silicone gel implants, associated with Thomas Cronin and Frank Gerow, entered the early 1960s as pre-filled devices. A pre-filled implant has a fixed shape and volume before it reaches the operating field. The surgeon must create an opening large enough to pass the device without damaging its shell and then make the pocket accommodate that selected size. This is workable, but it ties access, implant volume and pocket preparation together.
The inflatable concept separated those steps. An empty shell could be folded or introduced through a smaller incision, placed behind the breast tissue, and then filled with a sterile liquid. In principle, this offered several practical advantages:
- a smaller access incision than a comparable pre-filled implant might require;
- the possibility of adjusting the volume after the shell was in the pocket;
- an opportunity to correct modest left-to-right volume differences during the operation; and
- a device that could be stored and transported without a fixed gel volume inside it.
These were design advantages, not guarantees of a better cosmetic result. The final contour still depended on the shell, implant dimensions, fill volume, tissue coverage, pocket position, skin envelope and the patient’s starting anatomy. The historical value of the inflatable idea is that it addressed the mechanics of implantation directly: the device was made smaller for insertion by postponing the filler step.
Arion’s 1964 patent and 1965 clinical report
The literature generally attributes the first inflatable saline-filled breast implant to Henri-Gilbert Arion and Laboratoires Arion in France. Later reviews describe a French patent in 1964 and clinical use beginning in 1965. Arion’s presentation of a retromammary prosthesis in 1965 is cited as the first clinical report of the concept. Because the original report was in French and historical accounts rely partly on later summaries, the exact chronology should be expressed carefully: the device was patented in 1964, reported and used clinically in 1965, and subsequently adapted by other manufacturers.
The first commercial model is usually identified as the Simaplast implant. A later peer-reviewed report describing early devices gives a useful picture of its construction. It had a silicone elastomer shell approximately 0.50 mm thick, a filling tube permanently attached to the back of the implant, and a Teflon plug inserted into the tube after filling. The tube was then concealed in a pocket on the posterior surface. This was an ingenious attempt to turn a soft shell into a sealed implant after it had been placed, but every additional junction was also a possible site of failure.
The early filler was not always ordinary saline. Arion initially proposed a hypertonic solution containing dextran in normal saline, and later recommended normal saline alone. The evolution from a more complex solution to sterile physiological saline illustrates an important engineering principle: a filler must not only create volume; it must also be compatible with the body, predictable if it escapes and practical for clinicians to use. Modern FDA information describes saline-filled implants as silicone outer shells containing sterile saltwater, while noting that some products are filled during the operation and others are pre-filled. That current description should not be projected backwards as though every early device used an identical formulation or construction.
How the design differed from an early silicone gel implant
The early silicone gel implant and the early inflatable saline implant shared a silicone-based outer shell, but they behaved differently in the operating room and after shell failure.
Insertion and adjustment
A gel implant arrived with its filler already inside. A saline inflatable implant arrived with the potential to be inserted in a less bulky state and expanded after placement. That was the central reason inflatable devices appeared. The surgeon could also select a fill amount within the device’s intended range, which made intraoperative adjustment possible. However, the ability to add fluid did not eliminate the need for accurate measurements or an anatomically appropriate pocket. Overfilling or underfilling could alter the shell’s stresses and the visible or palpable result.
What happened after a leak?
With saline, a shell or valve failure could allow the saltwater to escape and the breast to deflate. The body can absorb sterile saline, but the empty shell does not repair itself. A visible loss of size or a shape change may make the failure easier to recognise than a gel rupture. With an early gel device, the gel’s viscosity could help the implant retain its overall form after a small shell problem, and the material might remain within the surrounding capsule. That could preserve the external appearance while making the rupture clinically silent.
The modern FDA continues to distinguish these patterns. It uses “deflation” specifically for saline-filled implants when saline leaks and the device partially or completely collapses. It also warns that silicone gel ruptures may be silent and may be difficult to detect by physical examination alone. These are general device behaviours, not a claim that every saline failure is immediately obvious or that every gel rupture is hidden.
Feel, folds and visibility
The filler also affects the mechanical feel of the device. Reviews of early saline implants describe the consistency on palpation as closer to water than to natural breast tissue. Patients and surgeons also reported fluid movement, folds, rippling and a greater tendency for the implant edge to be felt or seen when soft-tissue coverage was limited. A gel filler, especially as gel formulations evolved, was more viscous and often felt closer to breast tissue. Even so, “natural feel” was never determined by filler alone. A thin tissue envelope, a large implant, a superficial pocket or a visible shell edge can make either type noticeable.
The trade-off was therefore not simply “saline is safer” versus “silicone feels better.” Saline offered an insertion and failure-detection logic; gel offered a more tissue-like filler and greater shape retention after some shell injuries. Both remained silicone-shell medical devices with risks of infection, contracture, malposition, rippling, rupture and further surgery.
Why early inflatable devices deflated so often
The first generations show the cost of adding a filling system to an implant. A pre-filled gel implant has no post-placement fill tube that must be sealed. The Simaplast design needed a tube, plug and posterior concealment pocket. The shell also had to tolerate folding during insertion and repeated mechanical stress once inflated.
The published evidence is historically important but limited. In one report of 30 bilateral augmentation cases, 10% of the implants experienced early spontaneous deflation. A later report described a 76% spontaneous deflation incidence within three years for Simaplast implants. The latter figure is striking, but it belongs to a small, early model and an old series. It cannot be used as the deflation rate for all saline implants, all manufacturers or all eras.
The failure mechanisms helped direct subsequent development. Later reviews describe improvements involving room-temperature-vulcanised silicone shells and diaphragm valves. The aim was to reduce problems at seams and valves while keeping the device capable of being filled after insertion. That shift from a manually plugged tube to more reliable valve systems was not cosmetic tinkering; it was a response to a basic reliability challenge. The implant had to remain sealed for years while being thin and flexible enough to place through a relatively small opening.
Folds were another recurring issue. An underfilled inflatable implant can develop more pronounced shell folds. Repeated flexing at a fold may create fatigue and eventual rupture. Later clinical studies examined whether filling toward, or beyond, the manufacturer’s recommended range reduced deflation, but the results were not uniform and often came from retrospective cohorts using one device type. For example, a 2021 study of 4,761 aesthetic patients evaluated one Mentor saline model in a single-surgeon series; its design is useful for studying a mechanical question, but it cannot establish a universal fill rule. The sensible historical conclusion is narrower: fill volume and shell mechanics mattered, and the early device experience exposed that relationship. It is not evidence that a patient should request overfilling outside current product instructions.
From French innovation to broader use in North America
After the French development, saline implants were produced and evaluated by American manufacturers. Their use expanded in the United States and Canada, particularly during the period when access to silicone gel implants for cosmetic augmentation was restricted in the United States. That later popularity reflected regulatory and market circumstances as well as the original smaller-incision rationale.
An 11-centre retrospective outcomes study published in 1997 illustrates the difference between early historical prototypes and later clinical evaluation. It included 504 patients and 995 saline implants placed between 1980 and 1989, with most used for augmentation and a mean follow-up of six years. The study reported deflation, reoperation and capsular contracture, but it also had the limitations expected of a retrospective cohort: incomplete records, changing device models and techniques, and reliance on the patients and clinicians available for follow-up. Its results should be read as evidence about that cohort, not as a universal performance claim.
This distinction matters because “saline implant history” contains several different eras. Arion’s early device, 1970s and 1980s inflatable models, devices studied during the silicone restrictions and current approved products do not share identical shells, valves, surfaces, fill ranges or patient populations. A historical article should show how design decisions evolved without turning an old complication report into a current product comparison. The planned article on second-generation breast implants in the 1970s continues that technology sequence.
What the early saline story teaches about implant choice today
The first lesson is that a device can solve one problem while creating another. Inflatable saline implants made access and volume adjustment more flexible, but their valves, seams and folds required careful engineering. Silicone gel devices avoided the fill-valve problem and generally offered a more viscous feel, but a rupture could be harder to recognise and could be more difficult to remove if gel moved beyond the capsule.
The second lesson is to separate filler from the other implant variables. Current FDA information explains that both saline-filled and silicone gel-filled implants have silicone outer shells and may vary in size, shell thickness, surface texture and shape. Therefore, a discussion framed only as “saline versus silicone” misses the effects of dimensions, tissue coverage, pocket placement and surface.
The third lesson is that approval or popularity is not a lifetime guarantee. The FDA states that breast implants are not lifetime devices and that the likelihood of complications and additional surgery increases over time, although no one can predict an individual timetable. Patients need device-specific labelling, a record of manufacturer, model, filler, surface and size, and a plan for responding to a new change in shape, firmness, pain or swelling.
For practical anatomy and procedure context, readers can use the site’s breast augmentation operation information. A separate breast augmentation package page covers logistical planning rather than historical evidence. For a plain-language discussion of present-day filler differences, the existing silicone vs saline breast implants guide is the appropriate companion. The academic follow-up planned for this cluster is how the evidence evolved for silicone versus saline implants, which should examine rupture presentation, imaging and patient selection across eras rather than repeat this history.
Limitations of the historical evidence
The earliest device reports are not modern randomised comparisons. They include case series, retrospective cohorts, personal communications and later reviews that reconstruct events from incomplete records. Some publications combine cosmetic augmentation with reconstruction, while device generations and surgical techniques changed over time. Early deflation percentages can therefore describe a particular model’s experience without estimating the risk of a current device.
There is also a language and attribution limitation. Arion’s original 1965 report was published in French, and English-language histories commonly cite it through later reviews. The 1964 patent date and 1965 clinical-use date are consistent across the sources used here, but the exact sequence of commercial distribution and national adoption is less well documented than the central design concept. Claims in this article are intentionally limited to what the cited reviews and studies support.
Frequently asked questions
The article’s FAQ addresses when the first inflatable saline implant appeared, why saline devices were made inflatable, the problems reported in early models, the difference between saline deflation and silicone silent rupture, and whether saline implants remain in use. Answers are provided in the structured FAQ data for this article and are based on the sources and limitations described above.
Conclusion
Before silicone gel was placed inside a purpose-built shell, breast augmentation moved through a long period of experimentation. Dermal-fat flaps used the patient’s own tissue but required complex reshaping and could change over time. Injections were simple in concept but lacked containment and could cause diffuse, difficult-to-treat tissue reactions. Ivalon, Etheron, Polystan and polyethylene-based sponges offered a shaped prosthesis, yet tissue ingrowth and capsular contraction could produce firmness, shrinkage, distortion, erosion or discomfort.
Those failures created a clear demand for a contained implant, but they did not prove that the next generation would be risk-free. The most reliable historical conclusion is narrower: long-term breast augmentation requires more than immediate volume. It requires a material, shell, shape, tissue interface and follow-up plan that can be assessed over time. That principle remains relevant whenever a patient and surgeon discuss a modern implant.